Complement component C3 iRNA compositions and methods of use thereof
US11866701B2 · kind B2 · utility
1Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 1, 2018 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Feb 23, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/351
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement factor C3 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of a C3 gene and to treat subjects having a complement component C3-associated disease, e.g., paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica (NMO), multifocal motor neuropathy (MMN), myasthenia gravis (MG), and C3 glomerulonephritis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.